UroGen Pharma Ltd.

As of June 30, 2026, UroGen Pharma Ltd. carries a market capitalization of 1.60B, placing it among publicly traded companies globally. Its enterprise value stands at 1.68B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

UroGen Pharma Ltd.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, UroGen Pharma Ltd. has 48.87M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 9.80, and the price-to-book ratio stands at -13.81.

These figures are as of June 30, 2026. The EV/Sales ratio of 10.15 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.68B versus a market cap of 1.60B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, UroGen Pharma Ltd. maintains a current ratio of 3.80, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -148.14, indicating conservative leverage, while an interest coverage ratio of -3.95 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -42.33, reflecting losses generated across the asset base. The company generates approximately 596,385.81 in revenue per employee across its workforce of 277.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.09 indicates how many times UroGen Pharma Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, UroGen Pharma Ltd. recorded an income tax benefit of -413,141.60 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -85.87M and -85.46M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, UroGen Pharma Ltd.'s stock has gained approximately 101.49% over the past 52 weeks. The 50-day moving average sits at 36.81, while the 200-day moving average is 27.03.

Over the twelve months ended June 30, 2026, UroGen Pharma Ltd. generated 165.20M in revenue and converted that into -85.46M in net income, yielding earnings per share of -1.73. EBITDA reached -56.03M, while operating income came in at -58.34M.

As of June 30, 2026, UroGen Pharma Ltd. holds 94.51M in cash and equivalents against 171.67M in total debt, resulting in a net debt position of 95.93M. Total book value stands at -115.89M, with working capital of 151.87M providing operational flexibility.

UroGen Pharma Ltd. produced -139.10M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -190,815.40 in capital expenditures, free cash flow totaled -139.29M - equivalent to -2.82 per share.

Over the twelve months ended June 30, 2026, UroGen Pharma Ltd. posted a gross margin of 90.85, reflecting its pricing power and cost economics. The operating margin of -35.32 and net profit margin of -51.73 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -8.60: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -5.76, meaning UroGen Pharma Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, UroGen Pharma Ltd. has an Altman Z-Score of -1.98, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.